NBN and larynx cancer: In a large study aimed to assess the frequency of NBS1 mutations in patients with larynx cancer and multiple primary tumours, is emerged that the frequency of the I171V mutation carriers is significantly higher than in population controls (2.3% in larynx cancer patients, p=0.0175; 5.4% in multiple primary tumours, p=0.0005).